UNSPSC 51281662: Paromomycin i

This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61JJC8N5ZK, chemically known as diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine, but more generally known as paromomycin i, which bears US NIH Compound Identifier 4689.

European Medicines Agency schedules paromomycin i or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09630MIG. Most nations, for tariff purposes, schedule paromomycin i under HS 29419000. SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.

UNSPSC 51281662 Paromomycin I is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities posted under this code do not align with paromomycin procurement. The two recorded opportunities involve naloxone and safe drug deactivation systems (Seminole County, Florida), and doxycycline hyclate and ciprofloxacin hydrochloride tablets (Illinois Department of Public Health), neither of which is paromomycin. State and local governments use this code nominally to classify antibiotic or antimicrobial pharmaceuticals, but the available record shows no active demand for paromomycin specifically through recent solicitations. The opportunities that do appear reflect procurement of emergency-response medications and broad-spectrum antibiotics through piggyback cooperative purchasing agreements and competitive sealed bids.

Activity under this code tier remains sparse and geographically limited. The Seminole County procurement (Invitation for Bid, due July 26, 2023, for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida) and the Illinois Department of Public Health award to Chartwell Rx LLC (completed in August 2026 for $2,999,999.11 over three years via the MMCAP Infuse cooperative purchasing vehicle) represent the only recent state and local postings identified. No recent opportunities specifically target paromomycin procurement, suggesting limited current demand for this commodity under this code in state and local markets.